<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297216</url>
  </required_header>
  <id_info>
    <org_study_id>17-1173</org_study_id>
    <secondary_id>1R01HD087119</secondary_id>
    <nct_id>NCT03297216</nct_id>
  </id_info>
  <brief_title>Improving Pregnancy Outcomes With Progesterone</brief_title>
  <acronym>IPOP</acronym>
  <official_title>Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, double-masked, placebo-controlled, randomized controlled trial taking
      place in Zambia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Weekly intramuscular injections of 250mg 17-alpha hydroxyprogesterone caproate (17P) or
      indistinguishable placebo will be randomly allocated in a 1:1 ratio started between 16-24
      weeks gestation and administered weekly thereafter until 36 6/7 gestational weeks,
      stillbirth, or delivery, whichever is sooner.

      Individual participants will be followed from enrollment (prior to 24 weeks gestation)
      through 42 days postpartum.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, double-masked, placebo-controlled, randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Deliveries or stillbirths before 37 weeks gestation</measure>
    <time_frame>From date of randomization (between 16 and 24 weeks gestation) until delivery or stillbirth, up to a total of approximately 20 weeks, 6 days</time_frame>
    <description>Composite outcome of delivery and stillbirth before 37 weeks gestation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pre-term Birth</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>250 mg 17P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly intramuscular injection of 250mg 17P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>weekly intramuscular injection of indistinguishable placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17P</intervention_name>
    <description>Synthetic progestin</description>
    <arm_group_label>250 mg 17P</arm_group_label>
    <other_name>17-alpha hydroxyprogesterone caproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-active placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. less than 24 0/7 weeks of gestation

          3. viable intrauterine singleton pregnancy confirmed by ultrasound

          4. antibody-confirmed HIV-1 infection

          5. currently receiving ART or intending to commence ART in pregnancy

          6. ability and willingness to provide written informed consent

          7. intent to remain in current geographical area of residence for the duration of study

          8. willing to adhere to weekly study visit schedule

        Exclusion Criteria:

          1. confirmed prior spontaneous preterm birth

          2. multiple gestation

          3. known uterine anomaly

          4. planned or in situ cervical cerclage

          5. major fetal anomaly detected on screening ultrasound

          6. indication for planned delivery prior to 37 weeks (e.g. prior classical cesarean)

          7. threatened abortion, preterm labor, or ruptured membranes at time of enrollment

          8. known allergy or medical comorbidity listed as a contraindication to 17P in the
             prescribing information

          9. prior participation in the trial

         10. any other condition (social or medical) which, in the opinion of the study staff,
             would make trial participation unsafe or complicate data interpretation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Stringer, MD, FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bellington Vwalika, MBChB, MMed</last_name>
    <phone>+260 966 668 312</phone>
    <email>vwalikab@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kamwala District Clinic</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Price, MD</last_name>
      <phone>260 966 668 312</phone>
      <email>joan_price@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Price, MD</last_name>
      <phone>+260 966 668 312</phone>
    </contact>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PreTerm Birth</keyword>
  <keyword>HIV-1-infection</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

